About Us

We are transforming precision medicine

Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology.

Our proprietary whole genome analysis platform allows us to better understand a person’s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations.

Our Products

Learn More

Careers at Variantyx

Learn More

Our Mission & Values

Learn More

Our Team

Leadership at Variantyx

Our talented, interdisciplinary team of professionals has broad expertise in technology innovation, clinical genomics, bioinformatics, software engineering, information technology, and operations. We enable our customers to provide advanced diagnostics, offer precision treatment support, or gain insights to improve drug development.

Executive Team

Haim Neerman

CEO

Learn More

Haim Neerman

CEO |

Haim’s career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim co-founded Credorax Inc. – a global credit card acquiring bank, Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd. Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew University of Jerusalem.

Edward Sitar

CFO

Learn More

Edward Sitar

CFO |

Ed oversees global financial performance at Variantyx. Prior to his work at Variantyx, Ed served as the Chief Financial Officer of 9Meters Biopharma (Nasdaq:NMTR), a clinical stage company developing therapeutic approaches that treat people with rare and debilitating conditions by leveraging the biology of the gut. Ed is an experienced financial executive with an extensive healthcare background. He has led both public and private companies, raising substantial capital and improving operations. He holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey.

Yaron Rachmany

COO

Learn More

Yaron Rachmany

COO |

Yaron Rachmany oversees Operations, R&D, IT Systems and Security, Information Systems and Business Processes at Variantyx. Prior to joining Variantyx, Yaron served as Director of Systems Operations and as a Director of IT Applications at Semtech Corporation (NASDAQ: SMTC). Prior to Semtech Yaron held the VP of Information Systems position with Credorax. Prior to Credorax, Yaron held senior Information Systems positions with Microsemi (NASDAQ: MSCC), Intel (NASDAQ: INTC) and ECI Telecom. Yaron holds an M.Sc. and a B.Sc. in Industrial Engineering and Management (specialized in Information Systems) from Ben Gurion University in Israel.

Christine Stanley PhD, FACMG

Chief Director of Clinical Genomics

Learn More

Christine Stanley PhD, FACMG

Chief Director of Clinical Genomics |

As Chief Director of Clinical Genomics at Variantyx, Christine is responsible for overseeing clinical genomic interpretations and regulatory compliance for the clinical laboratory. Prior to joining Variantyx, Christine held positions as Head of Clinical Laboratory at WuXi NextCODE, Chief Director of Clinical Genomics at Courtagen Life Sciences and Genetics Director at Athena Diagnostics. Christine holds a Bachelor’s degree in Genetics from Texas A&M University and a PhD in Human Genetics from the Medical College of Virginia with fellowship training at Boston University in clinical molecular genetics. She is a diplomate of the American Board of Medical Genetics and Genomics and a Fellow of the American College of Medical Genetics and Genomics.

Christopher Zerwas

VP of Sales

Learn More

Christopher Zerwas

VP of Sales |

Chris serves as the VP of Sales. Chris’ primary focus is to drive revenue growth by leading a sales team to educate clinicians, and their supporting staff, about genomic testing capabilities and services at Variantyx. Chris brings 23 years of clinical genetic testing experience to Variantyx. Prior to Variantyx, Chris held senior sales management positions with PerkinElmer Genomics, GeneDx, and Athena Diagnostics. Chris holds a Bachelor’s degree in Marketing from Pacific University.

Tomer Jackman

VP Customer Support and Laboratory Services

Learn More

Tomer Jackman

VP Customer Support and Laboratory Services |

As VP Customer Support and Lab Services, Tomer is responsible for delivering services to customers. Prior to co-founding Variantyx, Tomer was responsible for hardware development operations in the Pivotal/Greenplum division of EMC2 where he helped develop server clusters for “Massive Parallel Processing” databases. This followed a decade with EMC2 in several hardware engineering roles and work in R&D with HP/Indigo. Tomer holds a high-tech MBA from Northeastern University in Boston, and a BSc in Electrical Engineering from Tel-Aviv University.

Tom DeLuca

Chief Human Resources Officer

Learn More

Tom DeLuca

Chief Human Resources Officer

Tom DeLuca serves as our Chief Human Resources Officer. Tom’s primary focus is to lead HR operations and oversee efforts surrounding organizational planning, DE&I, culture and engagement, recruitment, and learning as Variantyx grows. Prior to his time at Variantyx, Tom led the national sales and health plans organizations HR team for Quest Diagnostics, worked as VP of HR for Zelis Healthcare, and held senior HR positions with AIG, Cendant and Selective Insurance. Tom is a certified Myers-Briggs consultant and works to coach leaders on team effectiveness. Tom graduated from Kutztown University with a Bachelor’s degree in Business Administration.

Board of Directors

Haim Neerman

CEO

Learn More

Haim Neerman

CEO |

Haim’s career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim co-founded Credorax Inc. – a global credit card acquiring bank, Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd. Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew University of Jerusalem.

David Margulies, MD

Board Member

Learn More

David Margulies, MD

Board Member |

Prior to joining the Variantyx Board of Directors in late 2021, David Margulies, M.D. founded, co-founded, and participated as a Director and Senior Executive of a number of companies in the clinical computing, molecular diagnostics, and biotechnology fields. In the early 1980s, he co-founded and led BRS Medical, later acquired by WB Saunders and, ultimately, Elsevier North Holland. In the mid-1980s, while CIO at Boston Children’s Hospital, he led the design of software that was acquired by Cerner to be the basis of Cerner’s EMR. He became EVP, Chief Scientist, and a BOD member at Cerner in 1990. In 1996, he co-founded and was a Director of CareInsite, later acquired by WebMD in 2000. In 2000, he became co-founder, CEO, and Chairman of Correlagen Diagnostics, which was acquired by LabCorp in 2011 to be its genomic center of excellence. Dr. Margulies returned to Boston Children’s Hospital in 2011 as VP of Strategy and led the development of the institution’s genomic medicine strategy. In 2013, he co-founded and was Chairman of Q-State Biosciences, a Cambridge-based biotechnology company. Over the years, Dr. Margulies has served on numerous other public and private boards including D2 Hawkeye (acquired by Verisk), ObMedical (acquired by Philips), Circulation (acquired by Logisticare), Generation Health (acquired by CVS), Claritas Genomics (acquired by Q-State Biosciences), Travera, and Commonwealth Care Alliance. Dr. Margulies received his B.A. from Amherst College and his M.D. from Harvard Medical School. He completed his clinical training and board certification in Internal Medicine at Columbia College of Physicians and Surgeons. Dr. Margulies recently retired from the faculties of Genetics and Bioinformatics at the Harvard Medical School.

Guy Ezekiel, MD

Chairman

Learn More

Guy Ezekiel, MD

Chairman |

Guy is a Venture Partner at Pitango and the CEO of Zorro. Prior to that, he was a Managing Partner at Pitango HealthTech since May 2018. He currently serves on the Board of Directors of Alike, Laguna and Variantyx. Guy formerly served as the President and CEO of Ventor Technologies, a Pitango portfolio company and developer of revolutionary trans-catheter valves for the Cardiology market. In 2009 Ventor was acquired by Medtronic. Following the acquisition, Guy was appointed General-Manager/Vice President at Medtronic. During his career, Guy served as the President & CEO of Brainsway, President & CEO of Marval Pharma, and Senior Executive at the Pittsburgh headquarters of Medrad, Inc., a wholly-owned subsidiary of Bayer Healthcare. He holds an MD from Ben-Gurion University of the Negev and an MBA (cum laude) from the University of Pittsburgh.

Hillel Bachrach, MBA

Board Member

Learn More

Hillel Bachrach, MBA

Board Member |

Hillel is the Managing Partner of 20/20 HealthCare Partners, LLC, (20/20 HCP), a global investment entity he founded in 2005. 20/20 HCP has invested in many successful companies including Viztek (acquired by Konica Minolta in 2015), Corindus Vascular Robotics (purchased by Siemens HealthCare in 2019), XR Health, SQZ Biotechnology, Verseau Therapeutics and EnClear Therapies. In addition to Variantyx, Hillel currently serves on the Board of Directors for Zixi and Velocamp. Hillel previously served as president of Odin Medical Technologies, Inc., and helped found UltraSPECT, Ltd., the leader in providing sophisticated dose and procedure time reduction software solutions for nuclear medicine procedures which was sold to Pharmalogic in 2019. Hillel received a BS in electrical engineering from Technion Israeli Institute of Technology and an MBA from the Kellogg Graduate School of Management.

Zafrira Avnur, PhD

Board Member

Learn More

Zafrira Avnur, PhD

Board Member |

Chief Scientific Officer and partner at Quark Venture Inc.

Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering 2009 – 2016. She was responsible for creating relationships with the world’s leading academic institutions and world class innovators, gaining Roche early access to innovation. She has created eleven startup companies. Dr. Avnur was named Global Head of Neglected Diseases Roche Partnering 2010-2012. Preceding her academic innovation leadership role, Dr. Avnur assumed responsibility for scientific evaluations of partnering opportunities and started the “Finder” group for Biomarkers for all therapeutic areas at Roche. She acted as Liaison between Pharma and Diagnostic Divisions and contributed to the PHC (Personalized Health Care) initiative. Prior to her partnering roles, Dr. Avnur worked in pharmaceuticals and diagnostics research and development for nearly 20 years. She held number positions progressing from scientist and manager to global responsibilities. In this role, she was overseeing the advancement of compounds from the bench into the clinic, and was involved in the design and execution of early clinical studies that characterize the pharmacodynamics and clinical effects of a number of compounds. In her management roles, Dr. Avnur ran groups of up to 44 scientists. Dr. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche. Major scientific achievements include advancing three compounds (a PTHrP analog and two vitamin D analogs, for the treatment of postmenopausal osteoporosis) from early exploratory discovery research to the clinic.

Gideon Argov, MBA

Board Member

Learn More

Gideon Argov, MBA

Board Member

Managing Partner and Co-Founder at New Era

Gideon is also an Advisory Director of Berkshire Partners, an investment firm based in Boston. From 2004 to 2012 he was President and CEO of Entegris, a global supplier of products used in the production of high technology components and substrates. From 2001 to 2004 he was a Managing Director of Parthenon Capital, a private equity partnership based in Boston. From 1991 to 2000 he was Chairman, President and CEO of Kollmorgen Corporation, a supplier of high-performance electronic motion control products. Gideon is a serial angel investor in Israeli technology companies and served as the chairman of Fundtech and Servotronix. Gideon is the founder of the Shlomo Argov Fellows program for leadership in the public sector at Reichman University (IDC Herzliya) in Israel and a trustee of the Beth Israel Deaconess Medical Center in Boston. He received his BA from Harvard University (Economics, magna cum laude) and his MBA from the Stanford Graduate School of Business.

Investors

Variantyx is a privately-held, venture-backed company. We are supported by our international group of world-leading technology and healthcare investors.

Interested in learning more?

Read our case studies.

Learn More